Covax responds to the receipt of the NASDAQ delisting notification letter: has hired a new independent audit firm to meet NASDAQ compliance requirements.

Kexing announcement: Due to the failure to submit the annual report for the year 2024 by the extended deadline of November 11, 2024, Kexing Biotech received a delisting decision letter from Nasdaq on November 12, 2025. Unless it requests a hearing from the Nasdaq Hearings Committee, its securities will be suspended from trading and delisted as of the opening of trading on November 21. On November 19, a Kexing spokesperson told the Interface News that the Nasdaq delisting notice was related to the subsequent procedures following the delay in submitting the 2024 annual report due to the resignation of the auditing firm. The company had already made relevant disclosures earlier. Currently, the company has hired Uxin Certified Public Accountants as the new independent auditing firm and is working diligently to complete the audit and preparation of the annual report to meet Nasdaq's compliance requirements as soon as possible. The company has been in active communication with Nasdaq and will request an extension of the deadline for submitting the annual report and a hearing on the delisting matter as required. Today's announcement is a routine disclosure procedure to comply with regulatory requirements following the receipt of the delisting notice. The Kexing spokesperson emphasized that the company's listing status on the US stock market will not have a substantial impact on its core business operations. Currently, all operations such as vaccine research and development, production, supply, and market promotion under the Kexing group are proceeding normally, ensuring continued global product supply and support for public health services.